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Background: Diagnostic testing forms a major part of the UK’s 
response to the current coronavirus disease 2019 (COVID-19) 
pandemic with tests offered to anyone with a continuous cough, high 
temperature or anosmia. Testing capacity must be sufficient during 
the winter respiratory season when levels of cough and fever are high 
due to non-COVID-19 causes. This study aims to make predictions 
about the contribution of baseline cough or fever to future testing 
demand in the UK. 
Methods: In this analysis of the Bug Watch community cohort study, 
we estimated the incidence of cough or fever in England in 2018-2019. 
We then estimated the COVID-19 diagnostic testing rates required in 
the UK for baseline cough or fever cases for the period July 2020-June 
2021. This was explored for different rates of the population 
requesting tests, four COVID-19 second wave scenarios and high and 
low baseline cough or fever incidence scenarios. 
Results: Under the high baseline cough or fever scenario, incidence in 
the UK is expected to rise rapidly from 250,708 (95%CI 181,095 - 
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347,080) cases per day in September to a peak of 444,660 (95%CI 
353,084 - 559,988) in December. If 80% of these cases request tests, 
testing demand would exceed 1.4 million tests per week for five 
consecutive months. Demand was significantly lower in the low cough 
or fever incidence scenario, with 129,115 (95%CI 111,596 - 151,679) 
tests per day in January 2021, compared to 340,921 (95%CI 276,039 - 
424,491) tests per day in the higher incidence scenario. 
Conclusions: Our results show that national COVID-19 testing 
demand is highly dependent on background cough or fever incidence. 
This study highlights that the UK’s response to the COVID-19 
pandemic must ensure that a high proportion of people with 
symptoms request tests, and that testing capacity is sufficient to meet 
the high predicted demand.
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Introduction
In response to the spread of novel coronavirus severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), the United 
Kingdom (UK) has implemented large-scale public health meas-
ures that aim to reduce transmission and contact rates in the 
population. Maintaining control through diagnostic testing 
and self-isolation will increasingly depend upon self-diagnosis 
based on an individual’s symptoms. Current National Health 
Service (NHS) guidance is that any person in the community 
who develops at least one symptom of: a new continuous cough, 
a high temperature, or a loss of, or change in, normal sense 
of taste or smell (anosmia), should schedule a swab test with 
NHS services for home delivery or visit a testing site and self-
isolate for up to 10 days after onset of symptoms or until a 
negative test result is received1–3. The NHS Test and Trace serv-
ice aims to trace and notify close recent contacts of anyone 
who tests positive for coronavirus, instructing them to self- 
isolate for 14 days.
The importance of COVID-19 testing in the UK’s response 
to the current pandemic is apparent in the five-pillar test-
ing strategy, described by the UK Government in April 
2020. The first two pillars use swab-based testing and molecu-
lar diagnosis of COVID-19 using real-time PCR4. Pillar 1 of 
the testing strategy relates to the swab testing for health and 
care workers and those with a clinical need, carried out by 
Public Health England (PHE) and NHS labs. Pillar 2 concerns 
swab testing for the wider population including social 
care and is carried out with commercial partners. The UK 
Government stated that an important marker for easing control 
measures and restrictions included having confidence that 
operational challenges, such as testing capacity, were “in 
hand, with supply able to meet future demand”5.
Fever and cough are common symptoms in other acute respi-
ratory viruses6. As a result of the non-specific nature of these 
respiratory symptoms, a large number of individuals meeting 
the UK’s COVID-19 diagnostic testing criteria – and being 
subsequently tested – will have cough and/or fever caused by 
a non-COVID-19 infection. It is therefore important to esti-
mate the total number of cases in the population that would 
meet the diagnostic testing criteria (including both COVID-19 
and non-COVID-19 cases) and the proportion of these 
cases that would seek testing, in order to ensure sufficient 
diagnostic testing capacity.
Bug Watch was a prospective community cohort study 
conducted in England in 2018–2019 that collected daily 
information on symptoms of a range of acute common 
infections7. Data collected within the study allows us to esti-
mate the community incidence of fever and cough symptoms in 
England and describe seasonal patterns across a calendar year. 
Our study has two main objectives: first, to use Bug Watch data 
to estimate the all-age monthly incidence of cough or fever 
in England in the period 2018–2019; second, to estimate the 
UK COVID-19 diagnostic testing demand under current 
government testing policy for July 2020 – June 2021.
Methods
Study design, recruitment and data collection
Bug Watch was an online prospective community cohort 
study in England. Full details of the study design, recruitment 
and data collection are described in the protocol7. In brief, 
participants were recruited through an invitation letter sent to 
adults who participated in the 2013, 2014 and 2015 Health 
Survey for England (HSE). Parents or guardians were asked 
to register their children under 16 and complete surveys on 
their behalf. Any other adults within the same household were 
invited to register separately. Recruitment was conducted in 
four waves in March, June, September and November 2018. 
Data collected consisted of an online consent form and a base-
line survey followed by weekly surveys sent by email to be 
completed by each participant. Each week, participants were 
asked to prospectively keep track of a wide range of symp-
toms of infection using a symptom diary. The primary 
outcomes of interest for this study were cough (defined 
as either a dry cough or coughing up phlegm) and fever. 
Each individual was followed up for six months. Only indi-
viduals with a 75% completion rate were included in the 
analysis.
Out of 19,741 adults who were invited to join the study, 
a total of 873 participants were included in the analysis 
(782 adults and 91 children that they had registered), provid-
ing a total follow-up time of 23,111 person-weeks. Cohort 
baseline characteristics have been described in more detail8, 
and are included in Extended data, S19. In terms of indica-
tors of potential selection bias, participants were more likely 
to be older, female, healthier and living in less deprived areas 
than the general population of England. Age and sex were 
adjusted for in subsequent statistical analyses, but healthiness 
and deprivation levels may have skewed measured incidence 
rates in the cohort towards lower values than the general 
population.
Ethics
Data were collected using Research Electronic Data Capture 
(REDCap)17 surveys hosted on the UCL Data Safe Haven, 
which is certified to the ISO27001 information security stand-
ard and conforms to NHS Digital’s Information Governance 
Toolkit. This study was given ethical approval by the UCL 
Research Ethics Committee (ID 11813/001).
Statistical analysis
Baseline incidence of cough or fever in England. The first ten 
days of follow-up after each participant was recruited into the 
study were excluded to remove prevalent infection syndromes. 
For participants reporting cough or fever symptoms within 
these first ten days, follow-up was started on the first day 
          Amendments from Version 1
We have added an additional analysis to explore a low cough or 
fever incidence scenario (with an additional Figure 7) and have 
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after this period with no symptoms. Incident cough or fever 
were defined as i) when a participant reported cough or fever 
for the first time (one day of symptoms was recorded as 
a case); or ii) when either symptom was reported after a 
period of at least 10 days without symptoms. Non-specific 
symptoms could extend the duration of a cough or fever 
infection period. Public Health England reported that there 
were “low to moderate levels of influenza activity” in the 
2018-2019 influenza season, which was comparable to the 
2017-2018 season and higher than all other seasons since 
2010-201110.
Monthly adjusted incidence rates per 100,000-person-week 
for cough or fever and confidence intervals were calculated 
for England, weighting to the mid-2019 population structure 
of England for age, sex and region11 by post-stratification 
using a quasi-Poisson regression model (with the R ‘survey’ 
package version 4.012). Monthly age-specific incidence rates 
per 100,000-person-week for cough or fever in England were 
calculated, weighting by sex and region, and are included in 
Extended data, S29.
UK testing demand due to baseline cough and fever cases. 
Monthly all-age adjusted incidence rates of baseline (non-
COVID-19) cough or fever were estimated for the UK, 
weighting to the mid-2019 population structure of the UK 
for age and sex11. These rates were used to estimate the aver-
age number of individuals in the UK with an incident case of 
non-COVID-19 cough or fever each day for each month in the 
period July 2020 – June 2021.
Predictions for the daily testing demand expected in the UK 
between July 2020 and June 2021 due to baseline cough or 
fever cases were made based on our incidence estimates. We 
assumed that individuals only request a test on the first day 
that they experience symptoms. We explored a range of 
scenarios for the proportion of cough or fever cases that request 
a test (PROPTEST). Four values were explored: 40%, 60%, 
80% and 100%. The predicted impact of baseline cough or 
fever cases on UK testing capacity was calculated as the 
difference between UK Pillar 1 and 2 laboratory testing capac-
ity estimates from August 2020 and predicted testing demand 
between July 2020 and June 2021 based on these scenarios. 
Capacity estimates used in this analysis were reported by the 
UK government for the period 6–12th August 2020 as 1,459,418 
tests per week for Pillars 1 and 2, and 880,000 tests per week 
for only Pillar 213.
Total UK testing demand including symptomatic COVID-19 
cases. Four scenarios (C1–C4) for additional demand due to a 
second COVID-19 wave in the UK during winter 2020–2021 
were explored. A range of average daily incidences for 
COVID-19 cases for each month between July 2020 and 
June 2021 were considered to reflect uncertainty about future 
COVID-19 transmission levels, from the lowest in scenario 
C1 to the highest incidences in scenario C4. We used an 
exponentially weighted multiplication factor with minimum 
values of 0.002, 0.004, 0.006 and 0.008 in August for scenarios 
C1–C4, respectively, increasing to peak values of 0.05, 0.10, 
0.15 and 0.20 in January – March for these four scenarios. 
This multiplication factor was then multiplied by the estimated 
daily incidence of cough or fever in the UK for each month 
to provide hypothetical daily COVID-19 incidences for each 
month. An extended description of these methods can be found 
in Extended data, S39. These scenarios were selected to fol-
low a similar epidemic curve shape to predictions reported 
in the Academy of Medical Sciences’ report “Preparing for a 
Challenging Winter 2020/21”14, with the highest incidences 
in January and February 2021 and the peak incidence in our 
worst-case scenario (C4) equal to the peak incidence pre-
dicted in the report for a reproductive number R
t
=1.5 between 
September 2020 to July 2021. Based on estimates from 
the COVID Symptom Study app, 87.5% of these cases of 
COVID-19 were assumed to exhibit symptoms of cough, fever 
or loss of smell or taste15 with the proportion of these symp-
tomatic cases expected to request tests explored using the 
PROPTEST parameter. Total demand for swab tests due to 
baseline cough and fever cases and COVID-19 illnesses was 
calculated as:
Total demand =  (baseline cough or fever incidence + COVID19 
incidence × 0.875) × PROPTEST
The total predicted testing demand in each month was then 
calculated for each COVID-19 scenario (C1–C4).
Total UK testing demand in a low cough or fever incidence 
scenario. Estimated total UK testing demand was adjusted to 
explore the impact of a reduced incidence of baseline cough 
or fever cases relative to previous years due to social distancing 
and other COVID-19 public health interventions. Estimates 
of the relative reduction in monthly baseline cough or fever 
incidence for July – November 2020 compared to the corre-
sponding months in the 2018-2019 Bug Watch cohort were 
available from the preliminary results of the ongoing Virus 
Watch cohort study (see www.ucl-virus-watch.net for more 
information about the study) in England (unpublished report, 
author: Robert Aldridge). These found that the median 
reduction in non-COVID-19 cough or fever incidence in these 
months relative to the Bug Watch baseline was 73% (range 
34% - 81%). This was used to recalculate estimates of the 
total UK testing demand for each month assuming a 73% lower 
incidence of cough or fever relative to our historical baseline 
for each month.
All analyses were conducted using R version 3.6.316 using the 
R ‘tidyverse’ packages version 1.3.017.
Results
Cough or fever incidence in England
Out of a total of 585 episodes of cough or fever, participants 
experienced 431 (73.7%; 431/585) episodes of cough, 57 (9.7%; 
57/585) of fever and 97 (16.6%; 97/585) episodes with both 
cough and fever symptoms.
Monthly age-, sex- and region-adjusted incidence rates of 
cough or fever per 100,000-person-week and 95% confidence 
intervals are shown for the 12-month study period in England 
in Figure 1. There was clear seasonal variation in inci-
dence, with the lowest rates in June and highest rates in 
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Figure 1. Monthly adjusted incidence rates of cough or fever per 100,000-person-week in England with 95% confidence intervals. 
Weighted to the mid-2019 population structure of England by age, sex and region.
Figure 2. Predicted baseline number of individuals (in thousands) in the UK with an incident case of cough or fever each day 
shown for each month. Laboratory capacity (measured as daily tests) estimates from August 2020 for Pillars 1 and 2 and Pillar 2 in the UK 
are shown as solid and dashed red lines, respectively.
December with 1,333 (95%CI 753 - 2,361) and 4,958 (95%CI 
3,847 - 6,390) incident episodes of cough or fever per 
100,000-person-week, respectively. The high incidence in 
December coincides with UK public holidays and lower 
temperatures, when indoor contact rates are higher.
UK testing demand due to baseline cough and fever 
cases
Predictions for the average daily number of baseline 
(non-COVID-19) cough or fever cases in the UK between July 
2020 – June 2021 are shown for each month in Figure 2. Under 
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current UK government policy, all of these cases would be 
entitled to a COVID-19 swab test. After the lower incidence 
summer period of 2020, the incidence starts to rise rapidly, 
increasing from 154,554 (95%CI 103,083 - 231,725) cases 
per day in August to 250,708 (95%CI 181,095 - 347,080) in 
September, before peaking at 444,660 (95%CI 353,084 - 
559,988) daily cases in December. This high incidence contin-
ues to exceed UK laboratory testing capacity in August 2020 
for Pillars 1 and 2 until the end of winter before falling to 
204,750 (95%CI 141,392 - 296,499) cases per day in March 2021.
Remaining UK Pillar 1 and 2 capacity after testing baseline 
cough or fever cases is shown in Figure 3 for four values of 
the proportion of cough or fever cases which request tests 
(PROPTEST). The peak in cases in the autumn and 
winter of 2020–2021 is likely to place significant stress on 
the UK’s testing service in these months. Figure 3a shows 
that when only 40% of these cases request tests, capacity 
is sufficient for the entire year. However, as this propor-
tion increases, capacity becomes insufficient for predicted 
demand. When 60% request tests, demand in December 
2020 and January 2021 exceeds capacity by 58,308 (95%CI 
3,362 - 127,505) and 9,121 (95%CI -39,541 - 71,798) 
tests per day (Figure 3b). For 80% (Figure 3c), the 
daily average demand for tests exceeds capacity in five 
consecutive months (October 2020 to February 2021), with a 
peak of 147,240 (95%CI 73,978 - 239,502) tests per day 
above capacity expected in December 2020. If all individuals 
experiencing non-COVID-19 cough or fever request a test, we 
estimate that there will only be a significant capacity surplus in 
the summer months of July and August 2020 and June 2021.
Total UK testing demand including symptomatic 
COVID-19 cases
The four scenarios (C1-C4) for a winter COVID-19 epidemic 
in the UK which were explored in this study are shown in 
Figure 4. All scenarios follow the same epidemic curve shape 
with the highest average daily incidences between December 
2020 and March 2021 and peak incidences in January of 
18,134 (in scenario C1), 36,268 (C2), 54,402 (C3) and 72,536 
(C4) cases per day.
For the midrange C2 scenario, the remaining testing capacity 
available after testing baseline cough or fever cases and 
symptomatic COVID-19 cases is shown in Figure 5 (results 
for all other scenarios were similar and are included in Extended 
data, S49). These results were similar to those for baseline 
cough or fever cases only (Figure 3). Capacity is not predicted 
to be exceeded when only 40% of cough or fever cases and 
symptomatic COVID-19 cases request tests. When 60% 
of cases request tests, there is a predicted daily demand in 
December 2020 of 71,522 (95%CI 16,576 - 140,719) tests above 
capacity and the additional COVID-19 demand pushes total 
demand in February 2021 above capacity. When 80% of cases 
request tests, we see an increased deficit during the epidemic’s 
peak months of December to January and, when 100% request 
a test, UK testing capacity is predicted to be severely strained 
from September 2020 to May 2021.
Figure 3. Remaining UK Pillar 1 and 2 testing capacity (thousands of tests) available after testing baseline (non-COVID-19) cases 
of cough or fever in the UK each day. Panels a) to d) show results for four values of the proportion of cough of fever cases requesting 
tests (PROPTEST). Blue and red bars indicate that cough or fever testing demand is within or in excess of capacity available in August 2020, 
respectively.
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Figure 4. Four scenarios (C1 to C4) for average daily COVID-19 incidence in the UK shown for each month.
Figure 5. Remaining UK Pillar 1 and 2 testing capacity (thousands of tests) per day after testing baseline (non-COVID-19) cases 
of cough or fever and symptomatic COVID-19 cases in the UK each day for scenario C2. Panels a) to d) show results for four values 
of the proportion of cases requesting tests (PROPTEST). Blue and red bars indicate that testing demand is within or in excess of capacity in 
August 2020, respectively. Note that panel a) has a different y-axis scale to panels b) - d).
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The relatively small contribution of symptomatic COVID-19 
cases to total predicted testing demand in the UK for scenario 
C2 was also found for all other COVID-19 transmission sce-
narios, shown in Figure 6, for an assumed value of 80% of 
cases requesting a test. The more severe C3 and C4 scenar-
ios result in higher total demand in January 2021 of 328,227 
(95%CI 263,345 - 411,797) and 340,921 (95%CI 276,039 - 
424,491) tests per day, respectively, compared to 302,839 
(95%CI 237,957 - 386,409) in the C1 scenario. While these 
increases are not negligible, the total testing demand is predomi-
nantly driven by baseline cough or fever cases, and the overall 
effect of increased COVID-19 transmission between these 
scenarios is small. For example, in the highest transmission 
scenario, C4, and peak COVID-19 incidence in January 2021, 
only 14.9% of tests are expected to be requested by COVID-19 
cases. This is a result of the high incidence of baseline cough or 
fever cases during the second wave peak months of December 
2020 to February 2021. Consequently, relative to UK testing 
capacity in August 2020, the overall picture remains the same 
across the next year for all four scenarios, with the period 
October to February at high risk of surpassing UK testing 
capacity. As the proportion of cases requesting tests is applied 
to both baseline and symptomatic COVID-19 cases, sympto-
matic COVID-19 cases contribute the same proportion of the 
total testing demand for all other values of the proportions of 
cases requesting tests, although total demand varies significantly 
with this proportion (see Extended data, S59).
Total UK testing demand in a low baseline cough or 
fever incidence scenario
The low baseline cough or fever incidence scenario which 
explored the effect of a 73% reduction in cough or fever inci-
dence relative to the historical baseline is shown in Figure 7. 
For a C4 transmission scenario with 80% of cases request-
ing tests, the estimated total UK testing demand was below 
capacity reaching 129,115 (95%CI 111,596 - 151,679) tests 
per day in January 2021. This lower cough or fever inci-
dence scenario results in significantly lower levels of total test-
ing demand when compared to the high scenario estimates 
(Figure 6) which were based on the historical baseline cough 
or fever incidence. These lower estimated incidences of cough 
or fever would result in COVID-19 cases playing a more sig-
nificant role in driving testing demand, with COVID-19 
cases constituting 26%, 39%, and 39% of tests requested in 
December, January and February, respectively.
Discussion
In this study, we estimate the baseline incidence of cough or 
fever cases and their potential impact on COVID-19 diagnos-
tic testing services in the UK in July 2020 – June 2021. Our 
results show that if the baseline incidence of cough and fever 
between September 2020 and February 2021 is similar to inci-
dences in previous years, it may place a significant strain on 
UK testing capacity. Under these conditions we estimate that 
if more than 80% of people with symptoms request a test, 
Figure 6. Predicted daily testing demand (thousands of tests) due to baseline cough or fever cases (blue) and symptomatic 
COVID-19 cases (pink) in the UK, assuming that 80% of cases request tests. Panels a) to d) show results for scenarios C1 to C4. Daily 
UK Pillar 1 and 2 testing capacity estimates from August 2020 are marked with a red line.
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daily demand for COVID-19 swab tests will exceed the testing 
capacity available in August 2020 by a significant margin for 
five months. However, if the baseline incidence of cough or 
fever consistently remains at significantly lower levels than 
in previous years then capacity is likely to be sufficient. 
We find that testing demand in both baseline incidence sce-
narios will be predominantly driven by baseline cough or 
fever incidence, rather than symptomatic COVID-19 cases, 
and that the proportion of people with symptoms who request 
a test is a key determinant of demand. To our knowledge, this is 
the first paper published quantifying baseline cough or fever 
cases in the UK and their impact on COVID-19 diagnostic 
testing services.
The strong seasonal trend in baseline incidence of cough 
or fever cases in the UK is a clear indicator of the challenges 
which the UK’s testing services will face in the autumn and 
winter months of 2020–2021. Our results show that while the 
UK’s diagnostic testing capacity in August 2020 may be 
sufficient for July to September 2020, this is may not be the case 
during the winter period. If capacity is exceeded to the extent 
predicted in our results, a large backlog of unprocessed tests 
can be anticipated and a significant proportion of COVID-19 
positive cases are likely to remain untested. Prompt identifica-
tion of cases is critical for effective contact tracing and real-time 
visualisation of epidemiological trends to inform national and 
local-level public health interventions. It is therefore impera-
tive that the UK’s testing capacity continues to be scaled up 
to ensure that there is sufficient capacity to respond to this 
predicted rise in testing demand and ensure that the detection of 
COVID-19 cases is not compromised. Delays in testing, due to 
lack of capacity, will negatively affect the performance of the 
track and trace system, may also disincentivise people from 
getting tested and may result in unnecessarily extended 
self-isolation of COVID-19 negative households. The UK test-
ing strategy has acknowledged the need to expand testing 
capacity rapidly18 and appears to be on track to reach a PCR 
testing capacity of half a million tests per day by the end of 
202019. Our calculations show that if this additional capacity 
is achieved, it would significantly reduce the risk of testing 
backlogs over the winter period. However, under high levels 
of COVID-19 transmission and a baseline incidence of cough 
or fever which approaches historical levels, it is unlikely to be 
sufficient to also cover routine testing of asymptomatic health 
and care professionals20. Clearly, any improvements in the 
UK’s testing system must also be matched by the creation of an 
effective contact tracing system for identifying clusters at the 
local level and preventing onwards transmission, and by pro-
viding support to people to self-isolate – testing alone will not 
control transmission in the UK.
Our results show that testing demand is likely to be driven by 
the proportion of people with symptoms that request a test. 
An effective public health response to COVID-19 in the UK 
requires all individuals experiencing symptoms to request a test 
promptly after symptoms begin and our estimates for higher 
values of the proportion requesting tests should be considered 
as a necessary requirement for the UK’s testing capacity. 
Figure 7. Predicted daily testing demand (thousands of tests) due to baseline cough or fever cases (blue) and symptomatic 
COVID-19  cases  (pink)  in  a  low  baseline  cough  or  fever  incidence  scenario  (73%  lower  than  2018-2019  incidence)  in  the 
UK, assuming that 80% of cases request tests. 
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Therefore, in addition to scaling up capacity, the UK’s response 
must also ensure that a high proportion of symptomatic people 
are requesting tests to begin with. Estimates for this propor-
tion are not widely documented, but one recent study found 
that “that only about 40% of those who report classic COVID-19 
symptoms go on to receive a test”21. This low value is concern-
ing for COVID-19 control and would suggest that the results 
in our study for scenarios with lower values of the propor-
tion of cough or fever cases that request a test may be more 
accurate, and consequently that demand for testing would 
lie within capacity. However, understanding this test-seeking 
behaviour is clearly important and should be studied further 
through future weekly follow-up community studies structured 
similarly to the Bug Watch study. The potentially high 
baseline incidence of cough or fever cases reported in our 
analysis highlights the scale of this issue, and culturally and 
linguistically appropriate public engagement campaigns, as well 
as accessible and rapid test-ordering systems, will be critical to 
a successful response.
In this study, we explore a scenario in which the baseline 
incidence of cough or fever during the study period of 2018–19 
is representative of 2020–2021 and a second scenario in which 
the incidence during 2020-2021 is 73% lower. Which of 
these scenarios is most representative of demand in the winter 
2020-2021 is likely to depend on the type of public health 
restrictions which are implemented and how well they are 
observed by the UK population. The implementation of public 
health interventions in the UK during autumn 2020 varied 
geographically with an easing of restrictions in most of the UK 
during July–September 2020 followed by further restrictions 
in some higher transmission areas in November and December 
2020. Many measures, such as social distancing and bans on 
mass gatherings, will continue regardless of local restrictions. 
These public health interventions and changes in behaviour 
have been impacting upon the incidence of other respiratory 
pathogens globally, with reduced influenza activity reported in 
the United States, Australia, Chile and South Africa between 
June-August 202022 and UK surveillance data from 2019 
to 2020 suggesting low levels of influenza activity in the 
community23. This is consistent with the preliminary results from 
the Virus Watch cohort study which were used in the low inci-
dence scenario. The lowest reduction of 34% was in September 
2020 which may be explained by the fact that children and 
young adults can drive transmission of influenza and other 
seasonal respiratory infections. The reopening of schools and 
universities in the UK in September 2020 may therefore have 
maintained baseline cough or fever incidence in this month 
closer to 2018–19 levels. It is consequently likely that the future 
incidence of baseline cough or fever cases with an infectious 
aetiology will depend on the extent to which schools and uni-
versities are kept open. Our analysis provides estimates of pre-
dicted total testing demand for the reasonable best and worst 
case of baseline cough and fever incidence and clearly shows 
that the strain on testing capacity is highly dependent on the 
extent to which these other respiratory pathogens continue to 
be transmitted.
The COVID-19 transmission scenarios explored in this study 
are speculative and reflect uncertainty about the potential 
size and timing of a second COVID-19 wave. However, they 
present a range of reasonable scenarios based on previous 
modelling predictions14 that are consistent with the expecta-
tion that a second wave will have a lower peak incidence and 
flatter epidemic curve than the first wave in March – July 
2020 in the UK24. Our results show that total testing demand 
is relatively insensitive to COVID-19 transmission and that, 
even in more severe scenarios, testing demand due to baseline 
cough or fever cases will outweigh demand due to symptomatic 
COVID-19 cases.
A limitation of our study was that participants were more 
likely to be older, female, healthier and living in less deprived 
areas than the general population of England. To account for 
age and sex, we adjusted for these variables in our incidence 
estimates. There were also a disproportionately high number 
of white participants included in the study – meaning that eth-
nic minority communities that are known to have been particu-
larly adversely affected by COVID-19 were underrepresented25. 
Consequently, our results do not account for possible differences 
in the incidence of baseline cough and fever in these groups. 
Another possible limitation of this study is that a cough was 
defined as ‘incident’ rather than ‘continuous’ (lasting more than 
one hour or three or more coughing episodes in 24 hours), 
therefore potentially differing from the UK’s COVID-19 diag-
nostic symptomatology. We may consequently overestimate 
the number of cough cases who would require a test under 
current NHS guidance. We also note that our estimates of 
testing demand were largely driven by cough symptoms, 
as fever was comparatively less common. Data was not col-
lected on altered or lost sense of smell or taste, but we expect 
this to be rare in comparison to symptoms of cough or 
fever.
In conclusion, our study provides estimates of the baseline 
incidence of cough or fever in the general population in the 
UK. Our estimates indicate that, if baseline cough or fever 
incidence is maintained at 2018-2019 levels, the UK’s 
COVID-19 testing capacity in August 2020 is insufficient for 
high predicted demand in winter 2020-2021. However, if cough 
or fever incidence is maintained at the lower levels observed 
in October and November 2020 then it is likely to be suffi-
cient, even in the most severe COVID-19 transmission sce-
nario explored in this analysis. This study highlights the need to 
ensure that a high proportion of people with symptoms request 
tests and that sufficient testing capacity must be available for 
testing baseline cough or fever cases. Otherwise, compounded 
by high COVID-19 levels projected in a second wave, UK test-
ing capacity could be overwhelmed leading to failure of the 
NHS Test and Trace service and an inability to control the 
further spread of COVID-19.
Patient and public involvement
Participants were not directly involved in design of this 
study although feedback was collected at two time points during 
Page 10 of 22
Wellcome Open Research 2021, 5:225 Last updated: 21 JUN 2021
follow-up. Please see the Bug Watch community cohort study 
protocol for more information7.
Data availability
Underlying data
Open Science Framework: Impact of baseline cases of cough 
and fever on UK COVID-19 diagnostic testing rates: estimates 
from the Bug Watch community cohort study - Supplementary 
material, code and data. https://doi.org/10.17605/OSF.IO/5J6DY9
The repository contains the following underlying data:
•  data1_surv_com_week.csv (Survey completion rates)
•  data2_bl_exp.csv (Anonymised individual characteristics 
of participants)
•  data3_daily.csv (Daily symptom reports)
•  ONS_England_mid-2019_extracted_sex-reg-age.csv 
(Demographic data extracted from ONS mid-2019 
estimates for England, Source: Office for National 
Statistics licensed under the Open Government 
Licence v.3.0)
•  ONS_UK_mid-2019_extracted_sex-age.csv (Demo-
graphic data extracted from ONS mid-2019 estimates 
for the United Kingdom, Source: Office for National 
Statistics licensed under the Open Government 
Licence v.3.0)
•  Virus_watch_results_adj_month_2020-12-22.csv (Virus 
Watch cohort study estimates for the incidence of 
cough or fever cases in 2020).
•  VW_monthly_cough_prop.csv (Estimates of the 
proportion of cough or fever cases which are not 
COVID-19 cases from Virus Watch cohort study).
Extended data
Open Science Framework: Impact of baseline cases of cough 
and fever on UK COVID-19 diagnostic testing rates: estimates 
from the Bug Watch community cohort study - Supplementary 
material, code and data. https://doi.org/10.17605/OSF.IO/5J6DY9
This repository contains the R script used to conduct this 
analysis, supplementary material, underlying data and STROBE 
cohort study reporting checklist. 
This project contains the following extended data:
•  S1. Study population information
•  S2. Age-specific incidence rates of cough or fever
•  S3. COVID-19 incidences for scenarios C1 to C4
•  S4. Full exploration of proportion requesting test 
values for each scenario: C1, C3 and C4
•  S5. Full exploration of scenarios C1, C3 and C4 for 
each proportion requesting test value: 40%, 60%, 100%
•  S6. Estimated cough incidence rates in England
•  S7. Estimated fever incidence in England
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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General comment:
This is a clear and well-written paper that addresses an important issue. I agree with the 






If possible within the word count, it would be good to include that the pillars 1 plus 2 




‘The NHS Test and Trace service will trace and notify close recent contacts of anyone who 
tests positive for coronavirus to self-isolate for 14 days.’ It would be more correct to say that 
they ‘aim to’ rather than they ‘will’. Also, adding the words ‘instructing them’ to self-isolate 
would be less cryptic.  
 
○
Last paragraph, would it not be more correct to say ‘Bug Watch allows us to 
estimate’  (rather than quantify), as said later. The sample was 873 participants, with 
potential for selection bias, so extrapolating to the entire population and to different years 




There should be mention in the methods or results sections of whether, and potentially 
how, selection bias may have skewed the measured incidence rates in Big Watch. This is 
touched on in the discussion, but it would be better to state it earlier in the paper.  
 
○
Baseline incidence of cough or fever in England -  I found this paragraph hard to follow. I 
could not quite grasp how the term ‘follow-up’ was being used. Is this about excluding days 
from the denominator?  
 
○
Also, was cough or fever defined as any mention of these symptoms i.e. one day of 
reporting only? This needs to be specified in the methods section because this could be 
quite a ‘low bar’ for defining cough or fever. There is mention in the discussion, but I found 
it a bit ambiguous – was the ‘continuous’ cough definition used? This needs to be clear in 
the methods section.  
 
○
Also, mention of whether 2018/19 a high, low, or medium year for respiratory illnesses in 
general, would be helpful.  
 
○
Is it possible to use general practice morbidity data to add further insight into the 
relationship between the incidence of new cough or fever from the Bug Watch study, 
compared with GP consultation rates? This could give some insight into whether the 40, 60, 
or 80 percent seeking testing is most likely to be accurate. This is not an essential change, 
but would be a 'nice to have'. 
 
○
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At one point the term ‘antigen’ testing is used – does this mean PCR testing for viral RNA? It 
is potentially confusing to refer to this as antigen testing.  
 
○
The discussion only considers the need for greater testing capacity. It would be worth also 
mentioning the need to use tests to best effect. For example, as data develops on the 
predictive value of certain symptoms for ruling in and ruling out SARS-CoV-2 there may be 
scope for refining who should be offered a test e.g. cough with phlegm was presumably 
included in Bug Watch but is a dry cough more indicative of SARS-C0V-2? Also the timing of 
the test matters – if there is a delay in seeking a test then the result would not shorten the 
isolation period and it is too late to effectively act on all the contacts etc. Also, there has 
been considerable criticism of Test and Trace, so perhaps a phrase emphasising that a test 
alone is pointless. Testing must form part of a well-coordinated system that reliably leads to 
effective contact tracing, to prompt local action for dealing with clusters, and to support for 
those who are needing to self-isolate.  
○
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Public Health Screening Programmes, NHS Public Health service provision 
including general (non-specialist) communicable disease control.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
Author Response 15 Jan 2021
Max Eure, Lancaster University, Lancaster, UK 
Many thanks for the time you have spent reviewing our paper and your very helpful and 
constructive comments on the paper. We have tried to address all of the points you have 
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raised and to update the paper as much as is reasonably possible within the rapidly 
changing context. There is now an additional analysis which explores a lower (73% lower) 
cough or fever incidence scenario based on preliminary estimates from the Virus Watch 
cohort study we are running at UCL. We provide numbered point by point responses to your 
comments below. 
 
Reviewer comment 1:  
Abstract - If possible within the word count, it would be good to include that the pillars 1 
plus 2 capacity estimate being used is 1.4 million tests/week.  
 
Author response 1:  
This has been added. We have also made clear that this was the capacity in August 2020. 
  
Reviewer comment 2:  
Introduction - ‘The NHS Test and Trace service will trace and notify close recent contacts of 
anyone who tests positive for coronavirus to self-isolate for 14 days.’ It would be more 
correct to say that they ‘aim to’ rather than they ‘will’. Also, adding the words ‘instructing 
them’ to self-isolate would be less cryptic. Last paragraph, would it not be more correct to 
say ‘Bug Watch allows us to estimate’  (rather than quantify), as said later. The sample was 
873 participants, with potential for selection bias, so extrapolating to the entire population 
and to different years gives only an estimate. 
 
Author response 2:  
Thank you for these suggestions, we have added both of these corrections into the 
introduction. 
 
Reviewer comment 3:  
Methods - There should be mention in the methods or results sections of whether, and 
potentially how, selection bias may have skewed the measured incidence rates in Big Watch. 
This is touched on in the discussion, but it would be better to state it earlier in the paper. 
 
Author response 3:  
Thank you for this comment, we have highlighted the potential for selection bias and 
commented on its potential skew in the methods section. 
  
Reviewer comment 4:  
Methods - Baseline incidence of cough or fever in England -  I found this paragraph hard to 
follow. I could not quite grasp how the term ‘follow-up’ was being used. Is this about 
excluding days from the denominator? 
 
Author response 4:  
It should hopefully be clearer now that we excluded the first ten days for all participants 
after they entered the study - “The first ten days of follow-up after each participant was 
recruited into the study were excluded to remove prevalent infection syndromes.” 
  
Reviewer comment 5:  
Methods - Also, was cough or fever defined as any mention of these symptoms i.e. one day 
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of reporting only? This needs to be specified in the methods section because this could be 
quite a ‘low bar’ for defining cough or fever. There is mention in the discussion, but I found 
it a bit ambiguous – was the ‘continuous’ cough definition used? This needs to be clear in 
the methods section. 
 
Author response 5:  
Thank you for pointing this out - we have clarified that a single day of reporting the 
symptom counts as a case of cough or fever. The symptom definition used for cough is 
described in the first paragraph of the methods section. 
 
Reviewer comment 6:  
Methods - Also, mention of whether 2018/19 a high, low, or medium year for respiratory 
illnesses in general, would be helpful. 
 
Author response 6:  
Thank you for this helpful suggestion. Please see the sentence we have added in the 
methods section: “Public Health England reported that there were “low to moderate levels 
of influenza activity” in the 2018-2019 influenza season, which was comparable to the 2017-
2018 season and higher than all other seasons since 2010-2011”. 
 
Reviewer comment 7:  
Methods - Is it possible to use general practice morbidity data to add further insight into the 
relationship between the incidence of new cough or fever from the Bug Watch study, 
compared with GP consultation rates? This could give some insight into whether the 40, 60, 
or 80 percent seeking testing is most likely to be accurate. This is not an essential change, 
but would be a 'nice to have'. 
 
Author response 7:  
We have added a new reference in the discussion section which estimates  “that only about 
40% of those who report classic COVID-19 symptoms go on to receive a test”. We then 
comment on the implications of this on COVID-19 control and our results, and stress the 
importance of future studies looking at test-seeking behaviour and comment on how they 
can be structured. 
 
Reviewer comment 8:  
Discussion - At one point the term ‘antigen’ testing is used – does this mean PCR testing for 
viral RNA? It is potentially confusing to refer to this as antigen testing.  
 
Author response 8:  
This has been corrected. 
  
Reviewer comment 9:  
Discussion - The discussion only considers the need for greater testing capacity. It would be 
worth also mentioning the need to use tests to best effect. For example, as data develops 
on the predictive value of certain symptoms for ruling in and ruling out SARS-CoV-2 there 
may be scope for refining who should be offered a test e.g. cough with phlegm was 
presumably included in Bug Watch but is a dry cough more indicative of SARS-C0V-2? Also 
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the timing of the test matters – if there is a delay in seeking a test then the result would not 
shorten the isolation period and it is too late to effectively act on all the contacts etc. Also, 
there has been considerable criticism of Test and Trace, so perhaps a phrase emphasising 
that a test alone is pointless. Testing must form part of a well-coordinated system that 
reliably leads to effective contact tracing, to prompt local action for dealing with clusters, 
and to support for those who are needing to self-isolate.   
 
Author response 9:  
We have addressed this important point by inserting some additional text in the discussion 
which highlights that testing is only useful when accompanied by an effective contact 
tracing and a system which supports people to self-isolate.  
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Cheryl Cohen   
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the National Health Laboratory Service, Johannesburg, South Africa 
Impact of baseline cases of cough and fever on UK COVID-19 diagnostic testing rates: 
estimates from the Bug Watch community cohort study 
This paper uses data from a community cohort study to estimate the number of baseline cough 
and fever cases expected to occur in the 2020-2021 winter in the UK in order to infer the minimum 
COVID-19 testing capacity needed during the winter months. This is an important question and 
the approach taken is generally scientifically robust. The paper is nicely written and the approach 
is generally sound. I do have some suggestions below. 
 
Major comments 
The authors assume that the baseline rates of fever and cough in the upcoming winter will be 
similar to those of previous years with additional COVID-19-related burden superimposed. Data 
from the Southern Hemisphere 2020 winter however suggest that this may not be the case. Most 
Southern Hemisphere countries did not experience an influenza season in the 2020 winter and in 
many countries levels of ILI consultations were at all time low levels1. The authors should expand 
the abstract, introduction and discussion to consider this possibility further. It does not invalidate 
the relevance of the analysis but it should be clear that the projects presented may not be a true 
minimum estimate as it is possible that while COVID circulates other respiratory viruses may be at 
all-time low levels as may cases of fever and cough. The reason for the Southern Hemisphere 
observations are not known and it is also unclear what level of interventions will be in place to 
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control respiratory virus transmission during the upcoming UK winter season. Hence it is unclear 
whether the UK will see a reduction in respiratory illness. The authors should reposition the paper 
to include this possibility in introduction discussion and abstract. 
This should also be included as a scenario in the analysis – i.e. baseline fever and cough is 50% OR 
20% of historical numbers. 
 
Methods: UK testing demand due to baseline cough and fever cases – the authors explore a range 
of scenarios for the proportion of cough and fever seeking testing. I think the explored ranges are 
reasonable but can the authors provide some context please (perhaps from other studies) on 
proportion of fever and cough cases which usually seek medical care (and perhaps get a sample 
for testing) in UK and any estimates (if they exist) or thoughts of how health seeking could 
increase (or decrease) in response to COVID to help contextualise which of these estimates they 
think more likely. 
 
Could you use your study data from the summer period to look at the testing demand in the 
months which have already past? I.e. compare the rates for months which have past (March-
August) from your study to the actual demand for testing experienced to date in the UK to see 
how the numbers compare and inform our thinking about how they might compare going 




Discussion line 3 – suggest change “will place a strain” to may place a strain. 
 
Discussion – perhaps suggest some ways that UK could collect data on proportion of people with 
fever and cough who do get a test (e.g. through online platforms like your study) as these data 
may be useful to inform the public health response. 
 
Discussion paragraph 5: “Our results show that total testing demand is relatively insensitive to 
COVID-19 transmission” this is an interesting result – are there any published studies which have 
found this – perhaps again from the Southern Hemisphere – I agree this is what would be 
expected but it would interesting to see if this happened anywhere. COVID detection rates in 
different settings could be helpful but would need to know the case definitions used for testing 
and health seeking behaviour which data are generally not available. 
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Reviewer comment 1:  
General - The authors assume that the baseline rates of fever and cough in the upcoming 
winter will be similar to those of previous years with additional COVID-19-related burden 
superimposed. Data from the Southern Hemisphere 2020 winter however suggest that this 
may not be the case. Most Southern Hemisphere countries did not experience an influenza 
season in the 2020 winter and in many countries levels of ILI consultations were at all time 
low levels1. The authors should expand the abstract, introduction and discussion to 
consider this possibility further. It does not invalidate the relevance of the analysis but it 
should be clear that the projects presented may not be a true minimum estimate as it is 
possible that while COVID circulates other respiratory viruses may be at all-time low levels 
as may cases of fever and cough. The reason for the Southern Hemisphere observations are 
not known and it is also unclear what level of interventions will be in place to control 
respiratory virus transmission during the upcoming UK winter season. Hence it is unclear 
whether the UK will see a reduction in respiratory illness. The authors should reposition the 
paper to include this possibility in introduction discussion and abstract. This should also be 
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included as a scenario in the analysis – i.e. baseline fever and cough is 50% OR 20% of 
historical numbers. 
 
Author response 1:  
Thank you for this important comment. We have now thoroughly addressed this by 
discussing the possibility of low levels of other respiratory viruses and the implications of 
this throughout the paper and by adding an additional analysis. In this analysis we explore a 
low cough or fever incidence scenario (73% lower incidence than 2018-2019 levels) based on 
preliminary estimates from the Virus Watch cohort study we are running at UCL. 
 
Reviewer comment 2:  
Methods - UK testing demand due to baseline cough and fever cases – the authors explore 
a range of scenarios for the proportion of cough and fever seeking testing. I think the 
explored ranges are reasonable but can the authors provide some context please (perhaps 
from other studies) on proportion of fever and cough cases which usually seek medical care 
(and perhaps get a sample for testing) in UK and any estimates (if they exist) or thoughts of 
how health seeking could increase (or decrease) in response to COVID to help contextualise 
which of these estimates they think more likely. 
 
Author response 2:   
We have added a new reference in the discussion section which estimates  “that only about 
40% of those who report classic COVID-19 symptoms go on to receive a test”. We then 
comment on the implications of this on COVID-19 control and our results, and stress the 
importance of future studies looking at test-seeking behaviour and comment on how they 
can be structured. 
 
Reviewer comment 3:  
Methods - Could you use your study data from the summer period to look at the testing 
demand in the months which have already past? I.e. compare the rates for months which 
have past (March-August) from your study to the actual demand for testing experienced to 
date in the UK to see how the numbers compare and inform our thinking about how they 
might compare going forward. I.e. have the numbers to date been more or less than you 
would have predicted from your data? 
 
Author response 3:  
Thank you very much for this interesting suggestion. However, given the length of the 
paper in its current form and to limit the number of analyses within it we have decided not 
to carry out this additional analysis. 
 
Minor comments 
Reviewer comment 4:  
Discussion line 3 – suggest change “will place a strain” to may place a strain. 
 
Author response 4:  
We have added this suggestion. 
 
Reviewer comment 5:  
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Discussion – perhaps suggest some ways that UK could collect data on proportion of people 
with fever and cough who do get a test (e.g. through online platforms like your study) as 
these data may be useful to inform the public health response. 
 
Author response 5:  
We have added a new reference in the discussion section which estimates  “that only about 
40% of those who report classic COVID-19 symptoms go on to receive a test”. We then 
comment on the implications of this on COVID-19 control and our results, and stress the 
importance of future studies looking at test-seeking behaviour and comment on how they 
can be structured. 
 
Reviewer comment 6:  
Discussion paragraph 5 - “Our results show that total testing demand is relatively insensitive 
to COVID-19 transmission” this is an interesting result – are there any published studies 
which have found this – perhaps again from the Southern Hemisphere – I agree this is what 
would be expected but it would interesting to see if this happened anywhere. COVID 
detection rates in different settings could be helpful but would need to know the case 
definitions used for testing and health seeking behaviour which data are generally not 
available. 
 
Author response 6:  
We have been unable to find any published studies which have evaluated the sensitivity of 
testing demand to COVID-19 transmission and do not think we can explore this issue 
further in the discussion.  
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